Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Recursion Pharmaceuticals, Inc. (RXRX), covering cash flow, earnings, and balance sheets.
Recursion Pharmaceuticals, Inc. (RXRX) Income Statement & Financial Overview
Analyze Recursion Pharmaceuticals, Inc.’s RXRX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $19.22M | $14.74M | $4.51M | $26.08M |
| Cost of Revenue | $20.16M | $21.83M | $12.79M | $12.08M |
| Gross Profit | -$938000.00 | -$7.08M | -$8.28M | $14.003M |
| Gross Profit Ratio | -$0.05 | -$0.48 | -$1.84 | $0.54 |
| R&D Expenses | $128.64M | $129.63M | $98.33M | $74.60M |
| SG&A Expenses | $46.65M | $54.65M | $77.19M | $37.76M |
| Operating Expenses | $175.29M | $184.28M | $175.49M | $112.36M |
| Total Costs & Expenses | $195.45M | $206.11M | $188.31M | $124.44M |
| Interest Income | $0.00 | $0.00 | $4.62M | $3.83M |
| Interest Expense | $0.00 | $0.00 | $605000.00 | $553000.00 |
| Depreciation & Amortization | $0.00 | $19.33M | $12.95M | $7.20M |
| EBITDA | -$176.23M | -$182.81M | -$165.20M | -$87.92M |
| EBITDA Ratio | -$9.17 | -$12.40 | -$36.62 | -$3.37 |
| Operating Income | -$176.23M | -$191.37M | -$183.77M | -$98.35M |
| Operating Income Ratio | -$9.17 | -$12.98 | -$40.74 | -$3.77 |
| Other Income/Expenses (Net) | $4.33M | -$11.28M | $4.87M | $2.68M |
| Income Before Tax | -$171.90M | -$202.65M | -$178.90M | -$95.67M |
| Income Before Tax Ratio | -$8.94 | -$13.74 | -$39.66 | -$3.67 |
| Income Tax Expense | $0.00 | -$158000.00 | $7000.00 | $167000.00 |
| Net Income | -$171.90M | -$202.49M | -$178.91M | -$95.67M |
| Net Income Ratio | -$8.94 | -$13.73 | -$39.66 | -$3.67 |
| EPS | -$0.41 | -$0.50 | -$0.53 | -$0.34 |
| Diluted EPS | -$0.41 | -$0.50 | -$0.53 | -$0.34 |
| Weighted Avg Shares Outstanding | $417.36M | $402.77M | $336.04M | $282.58M |
| Weighted Avg Shares Outstanding (Diluted) | $417.36M | $402.77M | $336.04M | $282.58M |
Financial performance has remained strong, with revenue growing from $26.08M in Q3 2024 to $19.22M in Q2 2025. Gross profit continued to perform well, with margins at -5% in the latest quarter. Operating income reached -$176.23M in Q2 2025, holding a steady -917% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$176.23M. Net income rose to -$171.90M, keeping EPS at -$0.41. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan